Press Release|Articles|October 28, 2024
Camber Launches Generic Neurontin®
Listen
0:00 / 0:00
Key Takeaways
- Camber Pharmaceuticals introduces Gabapentin Oral Solution, expanding its existing gabapentin product offerings.
- Indications include management of postherpetic neuralgia in adults and adjunctive therapy for partial onset seizures in patients aged three and older.
Advertisement
Piscataway, NJ, October 25, 2024 – Camber Pharmaceuticals is pleased to announce the addition of Gabapentin Oral Solution to its product line. Camber also offers Gabapentin Tablets and Capsules.
Gabapentin Oral Solution is indicated for:
- Management of Postherpetic Neuralgia in adults
- Adjunctive therapy in the treatment of partial onset seizures, with and without secondary generalization, in adults and pediatric patients 3 years and older with epilepsy
Gabapentin Oral Solution is available in a 470 mL bottle with a concentration of 250 mg per 5 mL.
To learn more about Gabapentin Oral Solution, please visit
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Pharmacy Times
1
CKD Outcome Set Elevates Patient-Reported Measures
2
FDA Expands Accelerated Approval of Sevabertinib to First-Line HER2-Mutant NSCLC
3
In-Hospital Dapagliflozin Speeds Decongestion in Heart Failure
4
Tozorakimab Reduces COPD Exacerbations Across Eosinophil Levels in Phase 3 Trials
5